ADMA Biologics is trading 4.2% up at $9.29 as traders position ahead of its second-quarter 2026 earnings release scheduled for August 05, 2026.
- The stock is benefiting from a broader bid into the biotech sector, with the XBI sector ETF rising over 2%.
- Investors are awaiting management’s commentary regarding ongoing securities-fraud litigation.
- Market participants are focused on whether revenue and EPS results will meet current consensus expectations.